Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.

Burzynski SR, Burzynski GS, Janicki TJ, Marszalek A.

Pediatr Neurosurg. 2015;50(2):99-103. doi: 10.1159/000369907.

3.
4.
5.

Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth.

Burzynski SR.

Altern Ther Health Med. 2012 May-Jun;18(3):54-61. No abstract available.

PMID:
22875562
6.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
7.

Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.

Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.

Integr Cancer Ther. 2005 Jun;4(2):168-77.

PMID:
15911929
8.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
9.

Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.

Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.

Integr Cancer Ther. 2004 Sep;3(3):257-61.

PMID:
15312271
10.
11.

The present state of antineoplaston research (1).

Burzynski SR.

Integr Cancer Ther. 2004 Mar;3(1):47-58. Review.

PMID:
15035876
12.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
13.

Potential utility of antineoplaston A-10 levels in breast cancer.

Badria F, Mabed M, Khafagy W, Abou-Zeid L.

Cancer Lett. 2000 Jul 3;155(1):67-70.

PMID:
10814881
14.

Efficacy of antineoplastons A10 and AS2-1.

Burzynski SR.

Mayo Clin Proc. 1999 Jun;74(6):641-2. No abstract available.

PMID:
10377942
15.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

16.

Potential of antineoplastons in diseases of old age.

Burzynski SR.

Drugs Aging. 1995 Sep;7(3):157-67. Review. No abstract available.

PMID:
8535046
17.

Cellular accumulation of antineoplaston AS21 in human hepatoma cells.

Sołtysiak-Pawłuczuk D, Burzyński SR.

Cancer Lett. 1995 Jan 6;88(1):107-12.

PMID:
7850766
18.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

19.

The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.

Juszkiewicz M, Chodkowska A, Burzynski SR, Mlynarczyk M, Kleinrok Z.

Drugs Exp Clin Res. 1995;21(4):153-6.

PMID:
8529528
20.

The influence of antineoplaston A5 on the central dopaminergic structures.

Juszkiewicz M, Chodkowska A, Burzynski SR, Feldo M, Majewska B, Kleinrok Z.

Drugs Exp Clin Res. 1994;20(4):161-7.

PMID:
7813388
Items per page

Supplemental Content

Loading ...
Support Center